Medical Cannabis Payment Solutions (REFG) P/S Ratio
Medical Cannabis Payment Solutions (REFG) has a price-to-sales ratio of 13.23x, placing it in the Expensive range for cannabis stocks. The company has a market cap of $335.6M and TTM revenue of $1.95B. Revenue is declining 28.7% YoY.
P/S Ratio (TTM)
13.23x
EV/Revenue
9.68x
Market Cap
$335.6M
Revenue Growth
-28.7%
Valuation Breakdown
| Metric | Value |
|---|---|
| Stock Price | $29.28 |
| Market Capitalization | $335.6M |
| TTM Revenue | $1.95B |
| Price-to-Sales (TTM) | 13.23x |
| EV/Revenue | 9.68x |
| Revenue Growth (YoY) | -28.7% |
| Gross Margin | 8.5% |
| Sector | Ancillary |
| Exchange | OTC |
| Valuation Range | Expensive |
Frequently Asked Questions
What is REFG's current price-to-sales ratio?+
The price-to-sales (P/S) ratio divides Medical Cannabis Payment Solutions's market capitalization by its trailing twelve months of revenue. Since many cannabis companies are not yet profitable, P/S is one of the most widely used valuation metrics in the sector. A lower ratio may suggest the stock is undervalued relative to revenue.
How does REFG's P/S compare to other cannabis stocks?+
P/S ratios in cannabis typically range from 0.5x to 5x depending on growth rate, profitability, and market sentiment. High-growth companies command higher multiples, while mature, lower-growth companies trade at lower multiples. Compare Medical Cannabis Payment Solutions to peers in the same sub-sector (MSO, LP, ancillary) for meaningful context.
Is REFG overvalued or undervalued based on P/S?+
A single metric like P/S cannot definitively determine if Medical Cannabis Payment Solutions is over- or undervalued. Consider P/S alongside revenue growth rate, gross margins, cash position, and competitive dynamics. A company growing revenue at 50% YoY may justify a higher P/S than one growing at 5%. Also consider enterprise value-to-revenue (EV/Revenue) which accounts for debt and cash.